ERGOMED PLC LS -,01 chart

Last update: 2022-12-29
Key statistics and financials
Revenue per share 2.72
Dividend & YieldN/A€ (N/A)
Beta 0.93
Market capitalization 751.54M
Operating cash flow 15.54M
ESG Scores unknown

Company description

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Services and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 2.76M -2.38M 7.18M 217k
Total Cashflows From Investing Activities -3.79M -2.83M -12.78M -4.15M
Net Borrowings -12k -1.68M -2.19M -2.49M
Total Cash From Financing Activities 3.77M -250k -477k -2.11M
Change To Operating Activities 216k 126k -18k -298k
Issuance Of Stock 3.97M 1.43M 1.87M 546k
Net Income -8.98M 5.57M 9.68M 12.67M
Change In Cash 1.97M 9.07M 4.74M 12.25M
Effect Of Exchange Rate -111k 364k -60k -175k
Total Cash From Operating Activities 2.1M 11.79M 18.05M 18.68M
Depreciation 1.84M 2.88M 3.91M 4.47M
Change To Account Receivables -505k 1.88M -6.14M 367k
Other Cashflows From Financing Activities -187k -157k -157k -169k
Change To Netincome 6.08M 2.88M 2.5M 677k
Capital Expenditures -834k -392k -432k -953k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 1.58M 545k 152k 130k
Income Before Tax -10.77M 4.99M 12.63M 14.26M
Net Income -8.98M 5.57M 9.68M 12.67M
Selling General Administrative 17.46M 20.45M 25.33M 28.55M
Gross Profit 27.32M 38.47M 47.7M 66.39M
Ebit -1.04M 7.91M 14.39M 19.35M
Operating Income -1.04M 7.91M 14.39M 19.35M
Interest Expense -3k -273k -403k -361k
Income Tax Expense -1.79M -583k 2.95M 1.59M
Total Revenue 54.11M 68.25M 86.39M 118.58M
Cost Of Revenue 26.79M 29.79M 38.69M 52.19M
Total Other Income ExpenseNet -9.73M -2.93M -1.76M -5.08M
Net Income From Continuing Ops -8.98M 5.57M 9.68M 12.67M
Net Income Applicable To Common Shares -8.98M 5.57M 9.68M 12.67M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 18.5M 20.21M 39.48M 38.75M
Total Stockholder Equity 28.36M 36.82M 52.87M 67.24M
Other Current Liabilities 8.99M 5.39M 17.64M 20.77M
Total Assets 46.86M 57.03M 92.35M 105.99M
Common Stock 452k 473k 489k 493k
Other Current Assets
Retained Earnings -11.87M -5.5M 45.37M 59.06M
Treasury Stock 15.4M 16.06M 7.01M 7.14M
Cash 5.19M 14.26M 18.99M 31.24M
Total Current Liabilities 17.19M 15.86M 33.61M 35.38M
Other Stockholder Equity 15.4M 16.06M 7.01M 7.14M
Property, Plant, and Equipment 1.34M 6.28M 6.46M 4.66M
Total Current Assets 25.48M 32M 46.77M 60.34M
Net Tangible Assets 10.96M 20.68M 18.64M 35.68M
Net Receivables 19.06M 16.6M 26.3M 29.1M
Accounts Payable 4.38M 2.58M 4.2M 3.1M


Insider Transactions

Here are the insider transactions of stock shares related to ERGOMED PLC LS -,01:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Barfield (Richard Timothy)Exercise of Option at price 0.01 per share.D2022-12-02125k
Barfield (Richard Timothy)Sold at price 16.53 per share.D2022-12-02125k
Octopus Investments LtdD2022-10-19356.06k
Octopus Investments LtdD2022-10-13284.25k
Octopus Investments LtdD2022-10-11818.83k
Standard Life Aberdeen PlcD2022-08-3195.97k
Octopus Investments LtdD2022-08-18346.45k
Barfield (Richard Timothy)Sold at price 14.23 per share.D2022-07-2925k
Reljanovic (Miroslav)D2022-02-11150k
Standard Life Aberdeen PlcD2022-02-01236.91k
Standard Life Aberdeen PlcD2021-11-1853.44k
Jupiter Asset Management LtdD2021-10-20232.53k
Barfield (Richard Timothy)Sold at price 16.49 per share.D2021-08-1750k
Reljanovic (Miroslav)Sold at price 16.49 per share.D2021-08-171.2M
Standard Life Aberdeen PlcD2021-08-17468.09k
Standard Life Aberdeen PlcD2021-06-1685.77k
Aegon N.V.D2021-05-11
BlackRock, Inc.D2021-02-28
JPMorgan Asset Management U.K. LimitedD2021-02-28
Jupiter Asset Management LtdD2021-02-28
Slater Investments LtdD2021-02-28
Standard Life Aberdeen PlcD2021-02-28
Octopus Investments LtdD2021-02-28
Reljanovic (Miroslav)D2021-02-28
Slater Investments LtdD2021-02-231.21M
Soderstrom (Rolf Kristian Berndtson)D2020-12-31
Barfield (Richard Timothy)D2020-12-31
Johnson (Ian)D2020-12-31
Reljanovic (Miroslav)D2020-12-31

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to ERGOMED PLC LS -,01. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on ERGOMED PLC LS -,01

Here is the result of two systematic investment strategies applied to ERGOMED PLC LS -,01. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on ERGOMED PLC LS -,01

The following chart shows the equity curve of the two systematic investment strategies applied to ERGOMED PLC LS -,01:

ERGOMED PLC LS -,01 automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 366.07% on the backtest period.

Performance at glance

Performance

366.07 %

Latent gain

5489.29 €

Invested capital

1499.51 €

Annualized return

88.85 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on ERGOMED PLC LS -,01

This is the result of two momentum investment strategies applied to ERGOMED PLC LS -,01. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on ERGOMED PLC LS -,01

The following chart shows all the entries opened by the momentum investment system on ERGOMED PLC LS -,01:

ERGOMED PLC LS -,01 momentum entries
  • The first momentum investment strategy would give 378.0% of return on ERGOMED PLC LS -,01. That represents 15140.86€ of latent gain with 4005.54€ of employed capital.
  • The second momentum investment strategy would give 401.55% of return on ERGOMED PLC LS -,01. That represents 13041.29€ of latent gain with 3247.71€ of employed capital.
Performance at glance (1Q Momentum)

Performance

378.0 %

Latent gain

15140.86 €

Invested capital

4005.54 €

Annualized return

138.65 %
Performance at glance (2Q Momentum)

Performance

401.55 %

Latent gain

13041.29 €

Invested capital

3247.71 €

Annualized return

110.32 %

Momentum equity curve on ERGOMED PLC LS -,01

The following chart shows the equity curve of the two momentum strategies applied to ERGOMED PLC LS -,01:

ERGOMED PLC LS -,01 momentum equity

Note: the dividends potentially given by ERGOMED PLC LS -,01 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ERGOMED PLC LS -,01

The following chart shows the employed capital evolution of the two momentum strategies on ERGOMED PLC LS -,01 since the beginning:

ERGOMED PLC LS -,01

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on ERGOMED PLC LS -,01

Buy the dip entry openings on ERGOMED PLC LS -,01

ERGOMED PLC LS -,01

The performance achieved by the robo-advisor on ERGOMED PLC LS -,01 is 293.94%. That represents 733.32$ of latent gain with 249.48€ of employed capital. The following chart shows ERGOMED PLC LS -,01 stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of ERGOMED PLC LS -,01, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

293.94 %

Latent gain

733.32 €

Invested capital

249.48 €

Annualized return

138.65 %

Equity curve of the strategy applied to ERGOMED PLC LS -,01

The following chart shows the result of the investment strategy applied to ERGOMED PLC LS -,01:

ERGOMED PLC LS -,01

Note: the dividends potentially given by ERGOMED PLC LS -,01 are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ERGOMED PLC LS -,01

The following chart shows the employed capital evolution since the beginning of the investment strategy on ERGOMED PLC LS -,01:

ERGOMED PLC LS -,01

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on ERGOMED PLC LS -,01

In this section, I will compare the three previous investment strategies applied to ERGOMED PLC LS -,01.

Equity curve comparison on ERGOMED PLC LS -,01

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

ERGOMED PLC LS -,01 investment strategy comparison

Employed capital comparison on ERGOMED PLC LS -,01

ERGOMED PLC LS -,01 investment comparison

Performance comparison on ERGOMED PLC LS -,01

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 366.07% 5489.29€ 1499.51€ 88.85%
Momentum 1 quarter 378.0% 15140.86€ 4005.54€ 97.42%
Momentum 2 quarters 401.55% 13041.29€ 3247.71€ 110.32%
Non-directional 293.94% 733.32€ 249.48€ 138.65%
Annualized return comparison

Automatic investment

88.85 %

Momentum 1Q

110.32 %

Momentum 2Q

110.32 %

Non-directional

138.65 %

Correlated stocks

Here are the most positively and negatively correlated stocks with ERGOMED PLC LS -,01:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between ERGOMED PLC LS -,01 and the other stocks. There may be false positives or some missing correlated stocks. If the price of ERGOMED PLC LS -,01 does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name ERGOMED PLC LS -,01
Country United Kingdom
City Guildford
Address Surrey Research Park
Phone 44 1483 503 205
Website www.ergomedplc.com
FullTime employees 1371
Industry Biotechnology
Sector Healthcare
Exchange XETRA
Ticker 2EM.XETRA
Market www.xetra.com

ERGOMED PLC LS -,01 ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown